Torres JM, Sánchez C, Ramírez MA, Morales M, Bárcena J, Ferrer J, Espuña E, Pagès-Manté A, Sánchez-Vizcaíno JM (August 2001). «First field trial of a transmissible recombinant vaccine against myxomatosis and rabbit hemorrhagic disease». Vaccine19 (31): 4536-43. PMID11483281. doi:10.1016/S0264-410X(01)00184-0.
Sheridan C (February 2011). «Gene therapy finds its niche». Nature Biotechnology29 (2): 121-8. PMID21301435. doi:10.1038/nbt.1769.
«Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells». Gene Therapy18 (11): 1052-62. November 2011. PMID21490682. doi:10.1038/gt.2011.54.
«Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594». Current Pharmaceutical Biotechnology13 (9): 1768-72. July 2012. PMID21740365. doi:10.2174/138920112800958922.
Stephenson JR (March 2001). «Genetically modified viruses: vaccines by design». Current Pharmaceutical Biotechnology2 (1): 47-76. PMID11482348. doi:10.2174/1389201013378815.
Chan VS (November 2006). «Use of genetically modified viruses and genetically engineered virus-vector vaccines: environmental effects». Journal of Toxicology and Environmental Health. Part A69 (21): 1971-7. PMID16982535. doi:10.1080/15287390600751405.
Torres JM, Sánchez C, Ramírez MA, Morales M, Bárcena J, Ferrer J, Espuña E, Pagès-Manté A, Sánchez-Vizcaíno JM (August 2001). «First field trial of a transmissible recombinant vaccine against myxomatosis and rabbit hemorrhagic disease». Vaccine19 (31): 4536-43. PMID11483281. doi:10.1016/S0264-410X(01)00184-0.
Sheridan C (February 2011). «Gene therapy finds its niche». Nature Biotechnology29 (2): 121-8. PMID21301435. doi:10.1038/nbt.1769.
«Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells». Gene Therapy18 (11): 1052-62. November 2011. PMID21490682. doi:10.1038/gt.2011.54.
«Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594». Current Pharmaceutical Biotechnology13 (9): 1768-72. July 2012. PMID21740365. doi:10.2174/138920112800958922.
Stephenson JR (March 2001). «Genetically modified viruses: vaccines by design». Current Pharmaceutical Biotechnology2 (1): 47-76. PMID11482348. doi:10.2174/1389201013378815.
Chan VS (November 2006). «Use of genetically modified viruses and genetically engineered virus-vector vaccines: environmental effects». Journal of Toxicology and Environmental Health. Part A69 (21): 1971-7. PMID16982535. doi:10.1080/15287390600751405.
O'Riordan, Bernard (26 de febrero de 2005). «Virus planned to counter cane toad». The Guardian(en inglés británico). Consultado el 16 de diciembre de 2018.